|
|
|
|
|
 |
|
 |
 |
 |
 |
 |
 |
 |
|
|
|
 Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Our goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. We apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.
 08/07/2008 | Press Release JAZZ PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2008 FINANCIAL RESULTS - XYREM® SALES REACH RECORD $12.4 MILLION 07/24/2008 | Press Release JAZZ PHARMACEUTICALS, INC. TO ANNOUNCE SECOND QUARTER RESULTS ON AUGUST 7, 2008 07/21/2008 | Press Release JAZZ PHARMACEUTICALS ANNOUNCES CLOSING OF REGISTERED DIRECT OFFERING 07/16/2008 | Press Release JAZZ PHARMACEUTICALS ANNOUNCES $26.0 MILLION REGISTERED DIRECT OFFERING 06/11/2008 | Press Release JAZZ PHARMACEUTICALS FILES FORM S-3 REGISTRATION STATEMENTS |
|
© 2008 Jazz Pharmaceuticals, Inc. : Privacy Policy & Terms of Use | |
|
About Us : Our Products : News & Meetings : Partnering : Investors : Careers : Contact Us : Site Map | |
